Table 4.
Interventions during hospitalisation.
| Intervention | Number |
|---|---|
| Intravenous access | |
| Peripheral catheter | 39 (95%) |
| Duration (days), median (range) n = 39 | 4 (1–13) |
| Central venous catheter | 37 (90%)(plus 1/3 exported cases) |
| Subclavian vein | 24 (59%) |
| Interval jugular vein | 11 (27%) |
| Axillary | 1 (2%) |
| Unspecified | 2 (5%) |
| Central venous catheter inserted within 24 h | 31 (76%) |
| Duration (days), median (range) n = 41 | 5 (1–10) |
| Faecal collector system (rectal tube) | 21 (51%) |
| Duration (days), median (range) | 3 (1–10) |
| Urinary catheter | 27 (53%) |
| Duration (days), median (range) | 2 (1–10) |
| Intravenous (IV) fluid | 40 (98%) |
| IV Fluid maximum volume (L) in 24 h (median, range) | 3.2 (2–8) |
| IV Fluid median duration (days, range) | 5 (2–17) |
| IV Fluid median duration in survivors (days, range) | 5 (2–17) |
| Intravenous potassium (K+) replacement | 31 (76%) |
| Total K+ (mmol) during admission (median, range) n = 31 | 200 (20–640) |
| Intravenous magnesium (Mg2+) replacement | 18 (44%) |
| Total Mg2+ (mmol) during admission (median, range) n = 18 | 20 (16–156) |
| Intravenous phosphate (PO43-) replacement | 6 (15%) |
| Total PO43- (mmol) during admission (median, range) n = 6 | 50 (50–250) |
| Blood component therapy administered | 20 (49%) |
| Fresh frozen plasma | 18 (44%) |
| Cryoprecipitate | 9 (22%) |
| Platelets | 8 (20%) |
| Packed red blood cells | 2 (5%) |
| Intravenous Ceftriaxone | 37 (90%) |
| Median duration, days (range) | 5 (1–10) |
| Oxygen supplementation | 18 (44%) |
| Median duration, days (range) | 3 (1–7) |